Slides
Page 1
Alkem MedTechStrategic Way Forward 18thFeb 2026 Investor Meet
Page 2
2 Kaustav Banerjee: CEO, Alkem MedTech Pvt LtdA visionary business leader with a proven track record of building world-class organizations andestablishing robust industry presence across multiple geographies. Brings 26 years of transformativeexperience in the global medical device sector, with deep expertise in organizational scaling, market entry,and operational excellence.•Market Entry & Establishment- Founded and scaled the wholly-owned subsidiary of St. Jude Medical IndiaPvt. Ltd. from inception•Business Transformation- Spearheaded strategic transformation initiatives for Zimmer Biomet across theSouth Asia region, driving operational efficiency and market penetration•Multi-Geography Leadership- Over 17 years of executive experience managing complex, multi-countryoperations across diverse regulatory and market environments30+ years of experienceCEO – Alkem MedTech Pvt Ltd Kaustav Banerjee Key Positions Held –•Vice President (South Asia) and Managing Director (India) at Zimmer India Pvt. Ltd•Sr. Regional Director (South Asia & South East Asia, Hong Kong, Taiwan), St Jude Medical•Managing Director , St Jude Medical IndiaMedTech Platforms & Therapeutic areas –•Cardiology•Structural Heart•Electrophysiology•Orthopedics•Neuro Implantable
Page 3
3 Team: Alkem MedTech Swaminathan Nallasivam | Head - Sales & Marketing OrthoWith Alkem MedTech since 202427 years of experience30+ years of experienceCEO – Alkem MedTech Pvt Ltd Kaustav Banerjee Mohit Agarwal | Head - OperationsWith Alkem MedTech since 202417 years of experience Dr. Vilas Khade | Head - Regulatory & QualityWith Alkem MedTech since 202431+ years of experience Dhananjaya Shukla | R&D LeadWith Alkem MedTech since 202413+ years of experience
Page 4
4 Alkem Laboratories foray into MedTech space as natural progression for expansion$680Bn global MedTech market, projected to reach$870B by 2030High entry barriers create a defensible and resilient competitive positionStrong customer loyalty drives recurring revenue and long-term relationshipsConsolidated industry structure –limiting fragmentationContinuous Innovation sustains differentiation and margin strengthOpportunity & Competitive advantage Supportive government policies accelerating sector growth and localizationContinuously Evolving Reimbursement programs both at Center & State levelHigh import dependency creates strong domestic manufacturing opportunityCost-competitive manufacturing base enhances global competitivenessHigh EBITDA margins for scaled Indian players operating globallyTalent density across R&D, regulatory, quality, and precision manufacturingSource - BCG CII Aug 2025 Report GlobalIndia1630 2025 2030E +13% p.a. India market size ($ Bn)Global market breakup46%26%22% US EU APAC 5% Others
Page 5
5 Alkem MedTech has identified 2 priority segments to build its global presence Market Opportunity Market ($ Bn)Global IndiaOverall MedTech Market6801161Orthopedic4930.442Cardiovascular Market8710.7821BCG CII Aug 2025 Report; 2 Mckinsey Internal report 2024 for India; 3F&S Report;Entry into MedTech BusinessTarget Segments Musculoskeletal Cardio VascularIVD & Wound Care •Increasing disease awareness leading to higher screening and early diagnosis rates•Government Reimbursement programs eliminating economic access barrier•Continuous operator skill enhancement improving adoption of advanced technologies•Improving Health infrastructure with more focus in emerging markets•Decentralization of care, with growth of tertiary care centers in Tier-2 and Tier-3 cities eliminating geographic access barrier•Increasing medical insurance penetration, improving affordability and utilizationKey Growth Drivers for Emerging Markets
Page 6
6 Musculoskeletal Journey so farHybrid ApproachOrganic (Tech transfer)Manufacturing Asset Acquisition Global Expansion Application in process for Knee, Hip & Continuum of Care products - CE Approval for Knee & Hip- Expected timelines Q4 FY28- CIS Country approval for Knee & Hip- Expected timelines Q1 FY28 Going Forward Knee –Q2 FY27, Hip –Q4 FY27Launch Repeat Customers150+Performance Update (YTD Dec’25) 50% + 5 Year Vision State of the Art ManufacturingSequential implant growth of >50% Q-o-Q 10%250 K+Implants in 5 yearsMarket Share* in India by 5thYear4000+ImplantersFully Integrated Manufacturing 2028Rest of World Launch*Large Joints Market
Page 7
7 Alkem MedTech is poised to enter into Cardiovascular Business Cardiovascular Growth LeversAcquisition of an established Global Cardio AssetPortfolio Expansion via established PlatformCost Optimization Overall CV Market Size ($ Bn), 2025 Key Global Players Source : BCG Report Focused Segment$1.4Bn$0.7Bn
Page 8
8 Overview of the Cardiac Device Market Heart condition Treatment options Device types Structural heart defects Holes or unusual connections in the heart that people are born with. They affect how blood flows inside the heart Medications (rare), Open-heart surgery, Transcatheter device closure ASD, PFO, PDA, VSD Valve Disease Valves don’t open or close properly, making it harder for blood tomove in the right direction causing fatigue, shortness of breath, or heart failure Valve repair/replacement (surgery), TAVI, TMVR TAVI valves, TMVR clips Heart Failure Heart becomes too weak or too stiff to pump blood well leading to tiredness, swelling, and trouble in breathing Medication, ICD/CRT implants, Ventricular Assist Devices (VADs), AFR ICDs, CRTs, AFR, shunts, VADs Coronary Artery Disease Arteries that feed the heart get narrowed or blocked, usually by cholesterol leading to chest pain or heart attacks Medication, Angioplasty + stents, Bypass surgery Stents, Drug-Eluting Stents (DES) Arrhythmias Heart beats too fast, too slow, or irregularly, which can feel like fluttering or skipping and may increase stroke risk Pacemakers, ICDs, Ablation Pacemakers, ICDs Stroke Risk (from Atrial Fibrillation) AF can cause blood to pool in the heart, forming clotsthat maytravel to the brain and cause a stroke Blood thinners, LAA Closure LAA Devices
Page 9
OcclutechA Platform to access Global Cardiovascular Market and expand the current portfolio
Page 10
10 Occlutech| SnapshotOverview20+ Developed countriesFounded in 2003 50 Mn €* (Jan-Dec 2025) 200,000+ implants sold Net sales by channel (2025)Net sales by geography (2025)Distributor49%Direct51%EU71%MEA7%Americas14%APAC8%70% Sales from Western Europe, USA, Japan300+Employees14%CAGR (2021-25)3rdranked globally within Occluder space2ndranked in Europe within Occluder space Footprint Manufacturing FacilityResearch & Development Center Global supply hub 2*PFO expected approval - US FDA (Jun’ 27) & Japan (Dec’ 27)Clinical Center
Page 11
11 Occlutech| Strong in-house capability to deliver long term valueKey Pipeline Products –•LAA (Left Atrial Appendage), $1.4Bn Market Opportunity•VFR (Vascular Flow Restrictor)Key Patent Families –•Welding method (across all products)•Flex delivery system•Flex 2 Braiding Technology •Micro braiding machine•In-House Developed Mechanical Testing & Coating facility•Dedicated Clean Room Highest Quality standardsExperience & Seasoned Leadership TeamRobust Future PipelineStrong Patented Portfolio (200+ patents)Strong R & D Capability (15+ team)
Page 12
12 Occlutech| Robust Value Chain and a world-class global distribution platformMarketingDistributionoHigh Pedigree Marketing talents from global large MedTech innovators oproduct knowledge and medical educationoDirect Presence in Western EuropeoStrong Channel partner in USResearch & DevelopmentManufacturingMarket Accesso200+ active patentsoIn-house RnDFacility in Germany & IstanbuloImpressive track record of innovationoStrong Product Pipeline oHighly experienced Clinical team in USoBackward Integrated Plant with multiple braiding machine oRobust Quality StandardsoState of Art FacilityoPresence in high barrier entry established markets US Western EuropeJapanAustraliaMarketingDistributionoHigh Pedigree Marketing talents from global large MedTech innovators oproduct knowledge and medical educationoDirect Presence in Western EuropeoStrong Channel partner in USResearch & DevelopmentManufacturingMarket Accesso200+ active patentsoIn-house RnDFacility in Germany & IstanbuloImpressive track record of innovationoStrong Product Pipeline oHighly experienced Clinical team in USoBackward Integrated Plant with multiple braiding machine oRobust Quality StandardsoState of Art FacilityoPresence in high barrier entry established markets US Western EuropeJapanAustralia
Page 13
13 Closure of Hole Creating a HoleThe w“Hole” Story :Complete portfolio of minimally invasive cardiac devices Occlutech ASD OccluderAtrial Septal DefectOcclutech PFO OccluderPatent Foramen OvaleOcclutech AFR deviceHeart FailureOcclutech UNI OccluderAtrial Septal DefectOcclutech PDA OccluderPatent Ductus ArteriosusOcclutech PLD OccluderParavalvular Leak ClosureOcclutech mVSD/pmVSD OccluderVentricular Septal Defect Occlutech Pistol Pusher Flex Pusher II Occlutech Sizing Balloon (OSB) Occlutech Guide WireOcclutech Delivery Set (ODS) Implant portfolioAccessories
Page 14
14 Occlutech| Market Standing in Key MarketsMarket Top PlayersMarket Size *(USD Mn)% Market Share of OcclutechUSA230 2%Western Europe115 24%APAC (Excl India)165 <5%Central and Eastern Europe70 <5%India19 - Source : BCG Report*Includes ASD, VSD, PFO, PDA
Page 15
15 Transaction Rationale – Occlutech as the Platform for Alkem’s Global Cardiovascular StrategyPerfect Fit – Business SegmentLeadershipProduct Portfolio SynergiesAttractive Financial ProfileRight fit with Alkem MedTech’s Purpose of “Advancing Medical Technology Solutions for a Better Tomorrow”Leading position in the Structural Hearst Occluder market with global reach (#2 in Europe, #3 Globally)Complete portfolio of minimally invasive cardiac devices, compliant with highest quality standards enhanced by ongoing product development pipelineAlkem’s brand building capability, enormous reach, operational excellence and current global footprint will enable potential synergies and efficienciesAttractive financial profile characterized by growth & high gross margins with continuous management initiatives to optimize business model and maximize value creationMature Market approvalStrong in-house clinical trials team with proven CT expertise and securing established global market approvalsOperating Leverage Global Expansion “Go Deep & Go Wide”Established platform for New product launch Alkem’s path to SuccessAlkem’s path to SuccessAlkem’s path to Success
Page 16
16 Transaction TermsOn February 13, 2026, Alkem MedTech announced that it has executed a binding term sheet for a strategic investment that will result in the acquisition of a 51–55% stake in Occlutech Holding AG•Total equity value – € 180.70 Mn (Rs. 19,516 million)The transaction remains subject to entering into definitive agreements, conditions precedent, transaction being authorized by the statutory authority as part of the control of foreign investments in some of the geographiesThe acquisition will be funded through internal accruals and current cash balanceIt is expected that the acquisition would be completed after the regulatory approvals are obtained by June 2026.EUR/INR - 108
Page 17
17 What Next for Alkem MedTech Global Presence Manufacturing capabilities Continuous product Innovation Centre of Excellence OrthopedicsCardiovascular Alkem MedTech to be a growth enabler for Alkem GroupComprehensive PortfolioHigh Quality ProductsSkill DevelopmentStrong Ecosystem & Vertical Integration
Page 18
18 Representation Videos ASD OccluderPFO OccluderAFR Occluder StrokeOccluder Placement
Page 19
Thank You
Page 20
20 - a leading Global Pharmaceutical PlayerAlkem Laboratories Limited 4R&D centre 18Manufacturing sites across India & US; 6 USFDA approved sites5thLargest Pharma company in India in terms of %MS Rs. 129,645MnRevenue in FY24-25 Rs. 702,444 MnMarket capitalization (as on 11thFeb’26) >8,800 Stockists73Sales Depots & CFA7Central Warehouses Countries – Alkem’sglobal Footprint40+ >21,000 Employees globally Rs. 25,122 MnEBITDA in FY24-25 Source : 2024-25 Annual report
Page 21
21 Alkem BusinessesDomestic PharmaInternational SubsidiariesWellness MedTech BiosimilarsAPI